InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI and New York, NY, USA. Source
No articles found.
ILLUSIO is a plastic surgery simulation tool that enables a surgeon and patient to...
ILLUSIO is a plastic surgery simulation tool th...
At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing thera...
At Catabasis Pharmaceuticals, our mission is to...
Genmab is a publicly traded, international biotechnology company specializing in t...
Genmab is a publicly traded, international biot...
Alnylam is leading the translation of RNA interference (RNAi) into a whole new cla...
Alnylam is leading the translation of RNA inter...
Foamix Pharmaceuticals is a specialty pharmaceutical company, committed to address...
Foamix Pharmaceuticals is a specialty pharmaceu...
Calithera is a clinical-stage biopharmaceutical company pioneering the discovery a...
Calithera is a clinical-stage biopharmaceutical...
Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy ...
Atara Biotherapeutics is a leading off-the-shel...
Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on a...
Concert Pharmaceuticals is a clinical stage bio...
Equillium is a biotechnology company leveraging deep understanding of immunobiolog...
Equillium is a biotechnology company leveraging...
Arena Pharmaceuticals is driven to deliver novel, transformational medicines with ...
Arena Pharmaceuticals is driven to deliver nove...
Join the National Investor Network and get the latest information with your interests in mind.